S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.42 (-1.89%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.42 (-1.89%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.42 (-1.89%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
S&P 500   4,976.10 (-0.70%)
DOW   37,897.35 (+0.32%)
QQQ   415.42 (-1.89%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.81 (-4.75%)
BABA   68.49 (-0.57%)
T   16.30 (-0.18%)
F   12.06 (+0.00%)
MU   106.85 (-4.54%)
GE   146.98 (-3.90%)
CGC   7.93 (+1.28%)
DIS   111.72 (-0.63%)
AMC   3.18 (+8.90%)
PFE   25.74 (+1.38%)
PYPL   61.87 (-0.37%)
XOM   119.71 (+1.00%)
Free Trial

CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)
Free crsp Stock Alerts
$54.91
-1.25 (-2.23%)
(As of 12:34 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
May. 13Estimated
Actual EPS
(Feb. 21)
$1.10 Beat By $0.95
Consensus EPS
(Feb. 21)
$0.15
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CRSP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRSP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CRISPR Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20244($1.98)($1.19)($1.59)
Q2 20244($2.24)($1.13)($1.64)
Q3 20244($1.78)($1.12)($1.47)
Q4 20244($2.01)($0.80)($1.44)
FY 202416($8.01)($4.24)($6.13)
Q1 20252($1.73)($1.50)($1.62)
Q2 20252($2.26)($1.37)($1.82)
Q3 20252($1.36)($1.25)($1.31)
Q4 20252($1.66)($1.14)($1.40)
FY 20258($7.01)($5.26)($6.14)

CRSP Earnings Date and Information

CRISPR Therapeutics last announced its earnings data on February 21st, 2024. The reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analysts' expectations of $148.72 million. Its quarterly revenue was up 3253.3% compared to the same quarter last year. CRISPR Therapeutics has generated ($1.96) earnings per share over the last year (($1.96) diluted earnings per share). Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($6.24) to ($4.39) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off prior year's report dates.

CRISPR Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/13/2024
Estimated)		------- 
2/21/2024Q4 2023$0.15$1.10+$0.95$1.10$148.72 million$201.20 million
11/6/2023Q3 2023($2.04)($1.41)+$0.63($1.41)$5.05 million-
8/7/2023Q2 2023($2.13)($0.98)+$1.15($0.98)$1.80 million$70.00 million
5/8/2023Q1 2023($1.64)($0.67)+$0.97($0.67)$24.33 million$100.00 million  
2/21/2023Q4 2022($2.27)($1.41)+$0.86($1.41)$7.37 million$6.00 million  
11/1/2022Q3 2022($2.30)($2.24)+$0.06($2.24)$3.53 million$0.09 million
8/8/2022Q2 2022($2.23)($2.40)($0.17)($2.40)$2.20 million$0.20 million
5/9/2022Q1 2022($1.91)($2.32)($0.41)($2.32)$2.45 million$0.94 million
2/14/2022Q4 2021($1.74)($1.84)($0.10)($1.84)$5.39 million$12.90 million    
11/3/2021Q3 2021($1.75)($1.67)+$0.08($1.67)$3.85 million$0.82 million
7/29/2021Q2 2021$3.52$9.44+$5.92$9.44$678.05 million$900.70 million
4/26/2021Q1 2021($1.47)($1.51)($0.04)($1.51)$4.99 million$0.54 million

CRISPR Therapeutics Earnings - Frequently Asked Questions

When is CRISPR Therapeutics's earnings date?

CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off last year's report dates. Learn more on CRSP's earnings history.

Did CRISPR Therapeutics beat their earnings estimates last quarter?

In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) reported $1.10 earnings per share (EPS) to beat the analysts' consensus estimate of $0.15 by $0.95. Learn more on analysts' earnings estimate vs. CRSP's actual earnings.

How much revenue does CRISPR Therapeutics generate each year?

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $371.21 million.

How much profit does CRISPR Therapeutics generate each year?

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$153.61 million. CRSP has generated -$1.96 earnings per share over the last four quarters.

What is CRISPR Therapeutics's EPS forecast for next year?

CRISPR Therapeutics's earnings are expected to grow from ($6.24) per share to ($4.39) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CRSP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends